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Nothing is as exhilarating as the process of creation. There is
something that is absolutely thrilling when a concept that is
born inside one’s head takes shape in the outer world and
becomes its own self-standing entity. That is why the pursuits
of scientiﬁc inquiry, research and discovery are so exciting.
Iam,therefore, particularly pleased toannounce the launch of
Translational Psychiatry, the new sister journal of Molecular
Psychiatry. This launch is a case study example of the
self-perpetuating character of creativity that goes beyond a
starting birth point to take a life of its own. Translational
Psychiatry is the outcome of ideas that I have been cultivating
for years. It will in turn serve as the vehicle for publication and
dissemination of creative outcomes of others that will then be
the source of inspiration for an even greater number of people
to unleash their own scientiﬁc creativity, which is undeniably
always built on the foundation of existing work.
When I ﬁrst conceptualized Molecular Psychiatry in 1995
1
the journal title bordered on being contradictory. The
juxtaposition of the words ‘molecular’ and ‘psychiatry’—even
though not unprecedented—was certainly unusual and raised
many eyebrows. Several colleagues told me then that those
two words together represented an oxymoron. However, that
was the direction taken by the experts in the mainstream of
medical research. In the 1990s, there was a blind faith in
mechanistic work that would lead to breakthrough cures. We
were all so wrong! The hallmark of current biomedical
research is that the explosion in mechanism dissection that
occurred in the last three decades has miserably failed to
generate new cures or novel preventive strategies. The
examples of mechanistically based therapies are few and
far between. Trastuzumab (Herceptin, Genentech, South San
Francisco, CA, USA) is so repeatedly cited that a tipping point
has been reached in which continued exempliﬁcation of this
speciﬁc, toxic and expensive treatment of limited curative
value will only serve to highlight how small the number of
success stories that we can boast as justiﬁcation for
translational medicine is.
Hopefully, my new juxtaposition of ‘translational’ and
‘psychiatry’ will, in 2011, be well accepted from the outset. It
needs to be; in psychiatry, therapeutics is in dire straits. There
are no fair treatments for autism and Alzheimer’s. Patients
with schizophrenia are still treated with drugs that block
dopaminereceptors,withimmenseresourcespouredoverthe
last 60 years at dissecting mechanisms, pathways, correlates
and variations of a suboptimal, at best partially effective, and
non-curativeapproach.Thosesufferingfromdepressionhave
comparably bleak therapeutic prospects. Nobel laureate
Julius Axelrod, a member of Molecular Psychiatry’s Editorial
Board from the journal’s inception until his death in 2004,
2
discovered the principle of synaptic reuptake of monoamines
such as serotonin and norepinephrine in 1961. Now, 50 years
later, if a patient arrives in a psychiatrist’s ofﬁce, and a new
diagnosis of depression is made, what is the most likely
treatment? A serotonin or norepinephrine reuptake inhibitor!
Ketamine is currently being tested as a ‘novel’ treatment for
depression.
3–5 The ﬁrst use of that drug in humans was
reported in 1965
6y What happened? Where is the locus of
the grievous disconnect between the promise, accomplish-
ments, discoveries and billions of dollars spent in contempor-
ary neuroscience,whichfueledthe unprecedentedsuccessof
Molecular Psychiatry, and the abysmal lack of conceptually
novel therapeutics in psychiatry? In medicine, the pathway
between discovery and therapeutics has been referred to as
‘the valley of death’.
7 In psychiatry, that should be called the
‘cesspool of devastation.’
Paradoxically, as I make such pessimistic statements,
insidemeakernelofoptimismnotonlyexistsbutitalsogrows.
At present, the state of translation in our ﬁeld is such that, as
we continue to sink into a long day’s journey into the night, we
have reached the stage of utter darkness in which those who
became knowledgeable of the night are prescient that the
crackofdawnisimminent.Ibelongtothisgroupthatisimbued
with a sane and sober optimism: the dawn of translation in
psychiatry is forthcoming. Having worked full time my entire
life at the interface of the clinic and the lab, in the ﬁelds of
translational medicine and psychiatry, I have experienced the
thrill of translation ﬁrsthand. The joy of having prevented four
certain deaths with a novel translational treatment of mono-
genetically based obesity caused by leptin deﬁciency
8–10 is,
to date, the highlight of my career. When will investigators in
psychiatry feel the same type of elation as they bring perfectly
happy and productive lives to patients with autism, Alzhei-
mer’s, depression, bipolar disorder or schizophrenia? When
will we arrive at a place where the grass is really greener,
where accurate diagnoses lead to optimally personalized and
curative treatments?
Why am I so optimistic? Translational medicine, of which
translational psychiatry is a branch, became, within a
remarkably short time, a bona ﬁde area of medicine, with its
own body of knowledge, journals, societies, scientiﬁc meet-
ings, training programs, organized and well-funded centers,
institutes anddepartments. Itsimportance isdemonstrated by
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www.nature.com/tpthe recognition emanating from the formal proposal submitted
to the United States Congress for the establishment of a
new National Institutes of Health Center, the National
Center for Advancing Translational Sciences, advocated by
Francis Collins. One should stop and listen when such a
visionary physician–scientist, who inspired, organized and led
the worldwide effort to successfully achieve the hitherto
impossible sequencing of the human genome,
11 strongly
pursues a new direction. This journal was conceptualized just
before the emergence of the proposal for National Center
for Advancing Translational Sciences, demonstrating the
timeliness of efforts to streamline and organize translational
pathways.
I believe in a broad view of translation, which is very
different from purely applied science, drug development,
pharmaceutical research or commercialization. The motto of
the John Curtin School of Medicine, where I am based, is
‘Health Through Discovery.’Paraphrasing our motto,Transla-
tional Psychiatry—and translational medicine in general—
covers the entire pathway from discovery to health. We will
publish, in this exciting new journal, the full spectrum from
the most fundamental discovery to proof of principle, ﬁrst
in human studies (T1), then going to clinical trials (T2),
translation from clinical research to healthcare practice
guidelines and policy (T3), treatment evaluation (T4) and just
as the proof of the pudding is in the eating, so the proof of
translation is in worldwide implementation and the advance-
ment of global health.
In our logo and cover banner, we use an image of the pitui-
tary gland highlighted by in situ hybridization of interleukin 1
receptor antagonist mRNA.
12 The pituitary gland was chosen
notbecausewebelieveithasanythingtodowiththecausesof
psychiatric disorders; those are sadly still unknown. We use
images of the pituitary because it is par excellence the
prototypical translational interface, which in this case starts
with the process of neuroendocrine transduction. Signals that
are generated within the brain as the outcome of gene–
environment interactions are transduced within the hypotha-
lamus into neuronally synthesized hypothalamic releasing
hormones, which reach the pituitary gland through the
hypophyseal portal system. The pituitary then translates
central nervous system-derived inputs into multiple endocrine
axes that regulate all organs and systems. Likewise, Transla-
tional Psychiatry was created to be the key translational
interface in the ﬁeld.
Please participate in Translational Psychiatry as readers
and authors. The future is here, and we invite you to join this
newonlinejournalthatwill combine theexpertise oftheNature
Publishing Groupwith thesuccessofMolecularPsychiatry.To
get to this place where the grass is really greener, you can
send your work directly to Translational Psychiatry or submit
ﬁrst toMolecular Psychiatry.In thelast 6 months,we accepted
only 3% of submissions in Molecular Psychiatry. We are in a
position that truly outstanding papers, which are favorably
reviewed, cannot be accepted in Molecular Psychiatry simply
based on priority, as we just do not have the space. The
authorsofsuchpaperswillnowbeinvitedtorevisetheirpapers
and submit the revised manuscripts to Translational Psychia-
try. An editorial decision may then be made without further
externalreview.Notethatmostpapersthathavebeenrejected
in Molecular Psychiatry will continue to be rejected. Transla-
tionalPsychiatry is a sisterjournal of MolecularPsychiatry, not
a second-tier publication. We will accept in Translational
Psychiatry only outstanding work, which a couple of years ago
would have been published in Molecular Psychiatry and it is
not currently in that journal solely for space reasons. An
invitation from us to submit to Translational Psychiatry
represents formal recognition that the work has the highest
levels of intrinsic merit, impact and relevance.
Cautious investigators hesitate to send their work to new,
unproven titles that have not existed long enough to have an
impact factor (IF) or to even be indexed. When Molecular
Psychiatry was launched in 1996, some brave researchers
foresaw our success and made multiple submissions to us.
Now they can boast publications in the ﬁeld’s number one
journal, with an IF of 15.049. An additional example is
provided by our own research. We had two research articles
in Nature Medicine’s ﬁrst volumes
13,14 that were submitted
before that journal had an IF. Now Nature Medicine’s IF
of 27.136 is the number one in medicine, research and
experimental ﬁelds. That very wise move paid off superbly.
It will only become increasingly hard to publish in high-impact
journals. In psychiatry, we teach that past behavior is the best
predictor of future behavior. That being true, one can only
foresee a splendid future for Translational Psychiatry. Would
not it be advantageous for you to be part of our inevitable
success right from the outset?
Conﬂict of interest
The author declares no conﬂict of interest.
J Licinio
Department of Translational Medicine, John Curtin School of Medical Research,
Australian National University, Canberra, ACT, Australia
E-mail: julio.licinio@anu.edu.au
1. Licinio J. Mol Psychiatry 1996; 1: 1–3.
2. Coyle JT. Mol Psychiatry 2005; 10: 225–226.
3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al.
Biol Psychiatry 2000; 47: 351–354.
4. Kudoh A, Takahira Y, Katagai H, Takazawa T. Anesth Analg 2002; 95: 114–118.
5. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al. Science 2010; 329: 959–964.
6. Domino EF, Chodoff P, Corssen G. Clin Pharmacol Ther 1965; 6: 279–291.
7. Coller BS, Califf RM. Sci Transl Med 2009; 1: 10cm9.
8. LicinioJ,Caglayan S,OzataM,YildizBO, deMiranda PB,O’KirwanFetal.ProcNatlAcad
Sci USA 2004; 101: 4531–4536.
9. Paz-Filho GJ, Babikian T, Asarnow R, Delibasi T, Esposito K, Erol HK et al. PLoS One
2008; 3: e3098.
10. Paz-Filho GJ et al. Obes Rev; 17 March 2011; e-pub ahead of print; doi:1111/j.1467-
789x.2010.00840.x.
11. Collins FS, Morgan M, Patrinos A. Science 2003; 300: 286–290.
12. Wong M-L, Bongiorno PB, Rettori V, McCann SM, Licinio J. Proc Natl Acad Sci USA 1997;
94: 227–232.
13. Wong M-L, Rettori V, al-Shekhlee A, Bongiorno PB, Canteros G, McCann SM et al.
Nat Med 1996; 2: 581–584.
14. LicinioJ,Mantzoros C, Negra ˜o AB,Cizza G, Wong ML, Bongiorno PB etal. NatMed 1997;
3: 575–579.
Translational Psychiatry is an open-access journal
published by Nature Publishing Group. This work is
licensed under the Creative Commons Attribution-Noncommercial-
No Derivative Works 3.0 Unported License. To view a copy of this
license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Editorial
2
Transl Psychiatry